| Name | Title | Contact Details |
|---|
Isto Technologies, Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Saint Louis, MO. To find more information about Isto Technologies, Inc, please visit www.istotech.com
Rexton, Inc is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Community Medical Services is a CARF–accredited addiction treatment program providing services in the form of outpatient medication-assisted treatment and private one–on–one and group counseling, Intensive Out-Patient therapy (IOP) and Moral Reconation Therapy (MRT) to those seeking help with their substance use disorders. We have a total of 14 clinics throughout the United States. We have seven Arizona locations which cater to Phoenix, Glendale, Mesa, Scottsdale, and Tempe; a clinic in East Tucson, Northwest Tucson, Safford and Casa Grande; four clinics in Montana located in Missoula, Kalispell, Billings and Belgrade, which cater to clients in Bozeman and Helena; a clinic in Wasilla, Alaska catering to the Mat-Su Valley and Anchorage, and two clinics in North Dakota, one located in Minot, catering to clients in Williston and Bismarck and a clinic in Fargo, catering to clients from Fargo/Moorhead, West Fargo, Grand Forks, and Minnesota.
Beaverton Dental Equipment is a Beaverton, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.